Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Investing.com - Mizuho has raised its price target on EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) to $28.00 from $26.00 while maintaining an Outperform rating on the stock. The company’s shares, currently trading at $10.99, have shown remarkable momentum with a 69% surge over the past six months, according to InvestingPro data.
The adjustment follows EyePoint’s second-quarter 2025 financial results reported last week, which highlighted the previously announced completion of enrollment in the company’s second Phase 3 LUCIA study for Duravyu. InvestingPro analysis shows the company maintains a strong balance sheet with more cash than debt, though it’s currently experiencing accelerated cash burn.
Duravyu is EyePoint’s sustained release tyrosine kinase inhibitor (TKI) product being developed for wet age-related macular degeneration (wAMD). The company also reported lower operating expenses in its quarterly results.
Mizuho expressed continued confidence in EyePoint’s position in the competitive wet AMD market, citing three key advantages: robust Phase 2 data supporting Duravyu’s potential, a straightforward pivotal Phase 3 clinical development program that better represents real-world use, and a leading position for potential first approval of a TKI-based product for wAMD.
The research firm noted that EyePoint’s valuation remains "very attractive" despite the price target increase, supporting its continued Outperform rating on the stock. This view aligns with the broader Wall Street consensus, as analyst targets range from $23 to $68, with a Strong Buy recommendation. For deeper insights into EYPT’s valuation and 13 additional key metrics, check out the comprehensive Pro Research Report available on InvestingPro.
In other recent news, EyePoint Pharmaceuticals faced a tough second quarter in 2025 as the company’s financial results fell short of expectations. The company reported an earnings per share (EPS) of -$0.85, missing the forecasted EPS of -$0.81. Revenue for the quarter was $5.3 million, significantly below the anticipated $6.66 million. These results have been a focal point for investors and analysts alike. Despite the revenue miss, there have been no recent updates regarding mergers or acquisitions involving EyePoint Pharmaceuticals. Analyst firms have yet to provide any upgrades or downgrades following these results. The financial shortfall has sparked discussions about EyePoint Pharmaceuticals’ future strategies. Investors are closely monitoring the company’s next moves in light of these developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.